STE Stock Analysis: STERIS | NYSE
Medical Devices | NYSE, USA | Market Cap: 24.777m USD | 12M Return: -1.9% | IE00BFY8C754 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 164M
EPS Trend: 98.4%
Qual. Beats: 2
Rev. Trend: 95.8%
Qual. Beats: 1
Warnings
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
STERIS plc (NYSE: STE) is a global provider of infection prevention products and services, organized into three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. Its offerings span cleaning chemistries, sterility assurance products, endoscope reprocessors and accessories, sterilizers, washers, surgical tables and lights, and instrument repair and maintenance services, as well as outsourced sterile processing for hospitals and contract sterilization, process validation, and equipment support for medical device and pharmaceutical manufacturers. The company is headquartered in Mentor, Ohio, and serves healthcare providers, medical device and pharmaceutical manufacturers, and biopharmaceutical facilities across the United States, Ireland, and other international markets. Founded in 1985 and listed on the NYSE in 1992, STERIS sits within the Health Care Equipment sub-industry and benefits from a business model that combines capital equipment sales with recurring service revenue from maintenance contracts and industrial-scale contract sterilization, a mission-critical step in the production of single-use medical devices.
- Hospital procedure volumes drive Healthcare consumables and services revenue
- Medical device sterilization demand lifts Applied Sterilization Technologies margins
- Biopharma capex recovery supports Life Sciences segment revenue growth
| Net Income: 826.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA -0.49 > 1.0 |
| NWC/Revenue: 20.62% < 20% (prev 21.35%; Δ -0.73% < -1%) |
| CFO/TA 0.12 > 3% & CFO 1.29b > Net Income 826.9m |
| Net Debt (1.67b) to EBITDA (1.65b): 1.01 < 3 |
| Current Ratio: 2.05 > 1.5 & < 3 |
| Outstanding Shares: last quarter (97.6m) vs 12m ago -1.21% < -2% |
| Gross Margin: 44.56% > 18% (prev 44.29%; Δ 0.28% > 0.5%) |
| Asset Turnover: 58.38% > 50% (prev 54.78%; Δ 3.60% > 0%) |
| Interest Coverage Ratio: 20.52 > 6 (EBIT TTM 1.17b / Interest Expense TTM 56.9m) |
| A: 0.12 (Total Current Assets 2.48b - Total Current Liabilities 1.21b) / Total Assets 10.7b |
| B: 0.31 (Retained Earnings 3.30b / Total Assets 10.7b) |
| C: 0.11 (EBIT TTM 1.17b / Avg Total Assets 10.6b) |
| D: 2.11 (Book Value of Equity 7.26b / Total Liabilities 3.44b) |
| Altman-Z'' = 4.74 = AA |
| DSRI: 0.98 (Receivables 1.01b/947.3m, Revenue 6.17b/5.70b) |
| GMI: 0.99 (GM 44.29% / 44.56%) |
| AQI: 0.95 (AQ_t 0.55 / AQ_t-1 0.58) |
| SGI: 1.08 (Revenue 6.17b / 5.70b) |
| TATA: -0.04 (NI 826.9m - CFO 1.29b) / TA 10.7b) |
| Beneish M = -3.03 (Cap -4..+1) = AA |
As of November 09, 2026, the stock is trading at USD 252.30 with a total of 1,389,476 shares traded. Over the past week, the price has changed by +11.09%, over one month by +20.92%, over three months by +9.19% and over the past year by -1.91%.
Current recommended Stop Loss: 243.90 (which is 3.3% or 1.3 ATR below the current price).
STERIS has received a consensus analysts rating of 4.13. Therefore, it is recommended to buy STE.
- StrongBuy: 4
- Buy: 1
- Hold: 3
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 260.7 | 3.3% |
P/E Trailing = 31.066
P/E Forward = 22.4215
P/S = 4.1038
P/B = 3.354
P/EG = 1.9158
Revenue TTM = 6.17b USD
EBIT TTM = 1.17b USD
EBITDA TTM = 1.65b USD
Long Term Debt = 1.81b USD (from longTermDebt, last fiscal year)
Short Term Debt = 280.3m USD (from shortTermDebt, last quarter)
Debt = 2.20b USD (from shortLongTermDebtTotal, last quarter) + Leases 150.9m
Net Debt = 1.67b USD (calculated: Debt 2.20b - CCE 531.1m)
Enterprise Value = 26.4b USD (24.8b + Debt 2.20b - CCE 531.1m)
Interest Coverage Ratio = 20.52 (Ebit TTM 1.17b / Interest Expense TTM 56.9m)
EV/FCF = 28.22x (Enterprise Value 26.4b / FCF TTM 937.0m)
FCF Yield = 3.54% (FCF TTM 937.0m / Enterprise Value 26.4b)
FCF Margin = 15.20% (FCF TTM 937.0m / Revenue TTM 6.17b)
Net Margin = 13.41% (Net Income TTM 826.9m / Revenue TTM 6.17b)
Gross Margin = 44.56% ((Revenue TTM 6.17b - Cost of Revenue TTM 3.42b) / Revenue TTM)
Gross Margin QoQ = 44.74% (prev 45.84%)
Tobins Q-Ratio = 2.47 (Enterprise Value 26.4b / Total Assets 10.7b)
Interest Expense / Debt = 2.59% (Interest Expense 56.9m / Debt 2.20b)
Taxrate = 26.17% (294.1m / 1.12b)
NOPAT = 862.2m (EBIT 1.17b * (1 - 26.17%))
Current Ratio = 2.05 (Total Current Assets 2.48b / Total Current Liabilities 1.21b)
Debt / Equity = 0.30 (Debt 2.20b / totalStockholderEquity, last quarter 7.26b)
Debt / EBITDA = 1.01 (Net Debt 1.67b / EBITDA 1.65b)
Debt / FCF = 1.78 (Net Debt 1.67b / FCF TTM 937.0m)
Total Stockholder Equity = 7.20b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.83% (Net Income 826.9m / Total Assets 10.7b)
RoE = 11.48% (Net Income TTM 826.9m / Total Stockholder Equity 7.20b)
RoCE = 12.95% (EBIT 1.17b / Capital Employed (Equity 7.20b + L.T.Debt 1.81b))
RoIC = 9.10% (NOPAT 862.2m / Invested Capital 9.48b)
WACC = 5.94% (E(24.8b)/V(27.0b) * Re(6.30%) + D(2.20b)/V(27.0b) * Rd(2.59%) * (1-Tc(0.26)))
Discount Rate = 6.30% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -92.34 | Cagr: -0.80%
[DCF] Terminal Value 75.09% ; FCFF base≈946.7m ; Y1≈930.6m ; Y5≈944.8m
[DCF] Fair Price = 134.3 (EV 14.8b - Net Debt 1.67b = Equity 13.1b / Shares 97.5m; r=8.35% [WACC [floored]]; 5y FCF grow -2.52% → 2.50% )
EPS Correlation: 98.36 | EPS CAGR: 8.55% | SUE: 4.0 | # QB: 2
Revenue Correlation: 95.83 | Revenue CAGR: 9.48% | SUE: 1.78 | # QB: 1
EPS current Quarter (2026-12-31): EPS=2.80 | Chg30d=-0.17% | Revisions=+0% | Analysts=6
EPS current Year (2027-03-31): EPS=11.20 | Chg30d=+0.23% | Revisions=+25% | GrowthEPS=+10.1% | GrowthRev=+7.5%
EPS next Year (2028-03-31): EPS=12.33 | Chg30d=+0.69% | Revisions=+25% | GrowthEPS=+10.1% | GrowthRev=+6.7%
[Analyst] Revisions Ratio: +40% (up=2, down=0)